MCID: ESP025
MIFTS: 36

Esophagus Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Esophagus Adenocarcinoma

MalaCards integrated aliases for Esophagus Adenocarcinoma:

Name: Esophagus Adenocarcinoma 12 15
Adenocarcinoma of Esophagus 44 71
Oesophageal Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4914
MeSH 44 C562730
NCIt 50 C4025
SNOMED-CT 67 276803003
UMLS 71 C0279628

Summaries for Esophagus Adenocarcinoma

Disease Ontology : 12 An esophageal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Esophagus Adenocarcinoma, also known as adenocarcinoma of esophagus, is related to gastric adenocarcinoma and adenocarcinoma. An important gene associated with Esophagus Adenocarcinoma is HNF1A-AS1 (HNF1A Antisense RNA 1), and among its related pathways/superpathways are MicroRNAs in cancer and Central carbon metabolism in cancer. The drugs Cisplatin and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, colon and neutrophil.

Related Diseases for Esophagus Adenocarcinoma

Diseases related to Esophagus Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 318)
# Related Disease Score Top Affiliating Genes
1 gastric adenocarcinoma 30.4 TP53 PTGS2 FGFR2 ERBB2 CDX2
2 adenocarcinoma 30.4 TP53 PTGS2 HNF1A-AS1 FGFR2 ERBB2 CDX2
3 atrophic gastritis 30.4 TP53 PTGS2 CDX2
4 barrett's adenocarcinoma 30.2 TP53 TAGLN2 PTGS2 ERBB2 COX7A2
5 gastritis 30.2 TP53 PTGS2 CDX2 ATP4A
6 exanthem 30.2 ERBB2 ATP4A ATP12A
7 in situ carcinoma 30.2 TP53 MIR143 ERBB2
8 signet ring cell adenocarcinoma 30.2 TP53 ERBB2 CDX2
9 squamous cell carcinoma 30.2 TP53 PTGS2 HNF1A-AS1 FGFR2 ERBB2
10 peptic ulcer disease 30.1 TP53 PTGS2 ATP4A ATP12A
11 bile reflux 30.1 PTGS2 CDX2 ATP4A ATP12A
12 rectum cancer 30.1 MIR21 MIR145 MIR143
13 active peptic ulcer disease 30.1 PTGS2 ATP4A ATP12A
14 barrett esophagus 29.9 TP53 PTGS2 MIR196A1 ERBB2 CDX2 CDO1
15 colon adenocarcinoma 29.9 TP53 PTGS2 MIR21 ERBB2
16 body mass index quantitative trait locus 11 29.5 TP53 PTGS2 MIR21 MIR199A1 MIR196A1 MIR143
17 esophageal cancer 29.1 TP53 PTGS2 MIR330 MIR21 MIR199A1 MIR196A1
18 gastric cancer 28.9 TP53 PTGS2 MIR215 MIR21 MIR199A1 MIR145
19 bent bone dysplasia syndrome 10.5 FGFR2 ERBB2
20 her2-receptor positive breast cancer 10.4 MIR196A1 ERBB2
21 gastric papillary adenocarcinoma 10.4 TP53 ERBB2
22 laryngeal mucoepidermoid carcinoma 10.4 ERBB2 CDX2
23 adult teratoma 10.4 TP53 FGFR2
24 vulva adenocarcinoma 10.4 ERBB2 CDX2
25 apocrine adenosis of breast 10.4 TP53 ERBB2
26 vagus nerve disease 10.4 ATP4A ATP12A
27 necrotizing gastritis 10.4 ATP4A ATP12A
28 scalp dermatosis 10.4 ATP4A ATP12A
29 hemangioma of intra-abdominal structure 10.4 ATP4A ATP12A
30 acquired gastric outlet stenosis 10.4 ATP4A ATP12A
31 lingual goiter 10.4 ATP4A ATP12A
32 parotid gland cancer 10.4 TP53 ERBB2
33 displacement of cardia through esophageal hiatus 10.4 ATP4A ATP12A
34 bacterial esophagitis 10.4 ATP4A ATP12A
35 cascade stomach 10.4 ATP4A ATP12A
36 benzylpenicillin allergy 10.4 ATP4A ATP12A
37 median arcuate ligament syndrome 10.4 ATP4A ATP12A
38 afferent loop syndrome 10.4 ATP4A ATP12A
39 cervix erosion 10.4 ATP4A ATP12A
40 angiodysplasia of intestine 10.4 ATP4A ATP12A
41 granulomatous gastritis 10.4 ATP4A ATP12A
42 laryngeal tuberculosis 10.4 ATP4A ATP12A
43 fungal esophagitis 10.4 ATP4A ATP12A
44 dieulafoy lesion 10.4 ATP4A ATP12A
45 esophagus melanoma 10.4 ATP4A ATP12A
46 comedo carcinoma 10.4 TP53 ERBB2
47 emphysematous cholecystitis 10.4 ATP4A ATP12A
48 gastric gastrinoma 10.4 ATP4A ATP12A
49 superior mesenteric artery syndrome 10.4 ATP4A ATP12A
50 pneumatosis cystoides intestinalis 10.4 ATP4A ATP12A

Graphical network of the top 20 diseases related to Esophagus Adenocarcinoma:



Diseases related to Esophagus Adenocarcinoma

Symptoms & Phenotypes for Esophagus Adenocarcinoma

Drugs & Therapeutics for Esophagus Adenocarcinoma

Drugs for Esophagus Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
2
Epirubicin Approved Phase 2 56420-45-2 41867
3
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
4
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
5
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
6
Itraconazole Approved, Investigational Phase 2 84625-61-6 55283
7
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
8 Antibiotics, Antitubercular Phase 2
9 Anti-Bacterial Agents Phase 2
10 topoisomerase I inhibitors Phase 1, Phase 2
11 Antifungal Agents Phase 2
12
Hydroxyitraconazole Phase 2 108222
13 Cytochrome P-450 Enzyme Inhibitors Phase 2
14 Hormone Antagonists Phase 2
15 Anti-Infective Agents Phase 2
16 Hormones Phase 2
17 Cytochrome P-450 CYP3A Inhibitors Phase 2
18 Antineoplastic Agents, Immunological Phase 2
19
Etoposide Approved Phase 1 33419-42-0 36462
20
Gemcitabine Approved Phase 1 95058-81-4 60750
21
Capecitabine Approved, Investigational Phase 1 154361-50-9 60953
22
Levoleucovorin Approved, Investigational Phase 1 68538-85-2 149436
23
Fluorouracil Approved Phase 1 51-21-8 3385
24
Oxaliplatin Approved, Investigational Phase 1 61825-94-3 5310940 9887054 6857599 43805
25
leucovorin Approved Phase 1 58-05-9 6006
26
Docetaxel Approved, Investigational Phase 1 114977-28-5 148124
27
Paclitaxel Approved, Vet_approved Phase 1 33069-62-4 36314
28
Carboplatin Approved Phase 1 41575-94-4 10339178 498142 38904
29
Folic acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
30 Antimetabolites Phase 1
31 Etoposide phosphate Phase 1
32 Nutrients Phase 1
33 Protective Agents Phase 1
34 Immunosuppressive Agents Phase 1
35 Micronutrients Phase 1
36 Vitamin B Complex Phase 1
37 Immunologic Factors Phase 1
38 Trace Elements Phase 1
39 Tubulin Modulators Phase 1
40 Albumin-Bound Paclitaxel Phase 1
41 Vitamins Phase 1
42 Vitamin B9 Phase 1
43 Folate Phase 1
44 Antimitotic Agents Phase 1
45 Antidotes Phase 1
46
Tolnaftate Approved, Investigational, Vet_approved 2398-96-1 5510
47 Pharmaceutical Solutions

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 Phase II Trial of Cetuximab, Irinotecan, Cisplatin (CPC), Concurrent Radiation Therapy, and Surgery for Resectable Esophageal Cancer Completed NCT00165490 Phase 2 Cetuximab;Cisplatin;Irinotecan
2 Pre-operative Epirubicin, Capecitabine (Xeloda) and Cisplatin in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma Completed NCT00220103 Phase 2 epirubicin, capecitabine, cisplatin
3 A Randomised Phase 2 Trial Assessing REGorafenib Combined With IRInotecan as Second-line Treatment in Patients With Metastatic Gastro-oesophageal Adenocarcinomas Recruiting NCT03722108 Phase 1, Phase 2 Irinotecan
4 A Phase II Trial Evaluating the Effectiveness of Itraconazole in Improving Pathologic Complete Response Rates in Patients With Esophageal Cancer Through Inhibition of the Hedgehog and AKT Signaling Pathways Recruiting NCT04018872 Phase 2 Itraconazole
5 Multi-Modality Treatment of Resectable Oesophageal Adenocarcinoma Using Peri-operative Chemotherapy With Additional Pre-operative Combined Radiotherapy and Cetuximab Terminated NCT00827671 Phase 2 cetuximab
6 A Phase 1 Dose Escalation Safety Study Combining the ATR Inhibitor M6620 With Chemoradiotherapy in Oesophageal Cancer & Other Solid Cancers Using Time to Event Continual Reassessment Method Recruiting NCT03641547 Phase 1 M6620;Cisplatin;Capecitabine
7 A Phase 1 Study of NBTXR3 Activated by Radiotherapy With Concurrent Chemotherapy for Adenocarcinoma of the Esophagus Recruiting NCT04615013 Phase 1 Capecitabine;Carboplatin;Docetaxel;Fluorouracil;Leucovorin;Oxaliplatin;Paclitaxel
8 A Phase Ib Study of KD019 Plus Trastuzumab in Patients With HER2 Overexpressed or Amplified Metastatic or Unresectable Adenocarcinoma of Esophagus, Gastroesophageal Junction and Stomach Withdrawn NCT02205463 Phase 1 KD019
9 A Pre-operative Personalised Exercise Programme to Improve Physical Fitness and Reduce Post-operative Cardiopulmonary Complications After Oesophagectomy in Patients With Oesophageal Adenocarcinoma: A Feasibility Randomised Controlled Trial Unknown status NCT02962219
10 Effect of Neoadjuvant Chemotherapy on Muscle Mass and Peri-operative Cardiorespiratory Performance in Patients Undergoing Oesophageal Cancer- a Pilot Study Completed NCT01742312
11 'Pre-EMPT' - An Interventional Study to Assess the Effects of Pre-emptive Exercise , or 'Prehabilitation', in Patients Undergoing Peri-operative Treatment for Adenocarcinoma of the Oesophagus and Gastro-oesophageal Junction Recruiting NCT03626610
12 Impact of an Endoscopic Treatment of the Line Z on the Gastronomic Recurrence and the Gastro- Esophageal Reflux Disease in the Care of the Adenocarcinoma of Barrett's Oesophagus Recruiting NCT03278327
13 Study on Outcomes of Active Surveillance Among Invasive Locoregional Adenocarcinoma of Esophagus and Gastroesophageal Junction (GEJ) With Complete Response After Neoadjuvant Combined Chemoradiotherapy Terminated NCT02991547

Search NIH Clinical Center for Esophagus Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma of esophagus

Genetic Tests for Esophagus Adenocarcinoma

Anatomical Context for Esophagus Adenocarcinoma

MalaCards organs/tissues related to Esophagus Adenocarcinoma:

40
Lymph Node, Colon, Neutrophil

Publications for Esophagus Adenocarcinoma

Articles related to Esophagus Adenocarcinoma:

(show top 50) (show all 102)
# Title Authors PMID Year
1
MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. 47
20301167 2010
2
Gender Differences in Obesity-Related Cancers. 61
33523397 2021
3
Role of marital status on the prognosis in esophagus adenocarcinoma: a real-world competing risk analysis. 61
32892636 2020
4
The role of genetic polymorphism within PD-L1 gene in cancer. Review. 61
32679050 2020
5
Stromal microenvironment promoted infiltration in esophageal adenocarcinoma and squamous cell carcinoma: a multi-cohort gene-based analysis. 61
33122682 2020
6
Clinical profile of patients presenting with dysphagia - an experience from a tertiary care center in North India. 61
32514456 2020
7
Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus. 61
31664618 2020
8
Current Status of Mucosal Imaging with Narrow-Band Imaging in the Esophagus. 61
32307976 2020
9
Impact of Lymphadenectomy on Survival After Unimodality Transthoracic Esophagectomy for Adenocarcinoma of Esophagus. 61
31605326 2020
10
Size and Importance of Socioeconomic Status-Based Disparities in Use of Surgery in Nonadvanced Stage Gastrointestinal Cancers. 61
31605347 2020
11
Shared Genetic Etiology of Obesity-Related Traits and Barrett's Esophagus/Adenocarcinoma: Insights from Genome-Wide Association Studies. 61
31748258 2020
12
Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis. 61
31619265 2019
13
A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. 61
31036088 2019
14
Allergies and the Subsequent Risk of Cancer among Elderly Adults in the United States. 61
30700443 2019
15
Desmoplasia and Detached Papillae in Early Esophageal Adenocarcinoma: A Histologic Study on Endoscopic Submucosal Dissection Specimens. 61
31019616 2019
16
A Randomized Placebo-Controlled N-of-1 Trial: The Effect of Proton Pump Inhibitor in the Management of Gastroesophageal Reflux Disease. 61
31929980 2019
17
A six-microRNA signature can better predict overall survival of patients with esophagus adenocarcinoma. 61
31380150 2019
18
Barrett's Esophagus in Patients with Gastroesophageal Reflux Disease. 61
29983427 2018
19
The arachidonic acid metabolism protein-protein interaction network and its expression pattern in esophageal diseases. 61
29636881 2018
20
Histopathological Assessment for Esophageal Adenocarcinoma. 61
29600360 2018
21
Obesity and Cancer: Evidence, Impact, and Future Directions. 61
29038151 2018
22
Preliminary evaluation for Bit1 as a potential biomarker for squamous cell carcinoma and adenocarcinoma of esophagus. 61
28488526 2017
23
The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma. 61
28184414 2017
24
C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis. 61
27636117 2017
25
Epigenetic regulation on the gene expression signature in esophagus adenocarcinoma. 61
28049580 2017
26
Oral squamous cell cancer protein-protein interaction network interpretation in comparison to esophageal adenocarcinoma. 61
28744358 2017
27
Racial Differences in Esophageal Squamous Cell Carcinoma: Incidence and Molecular Features. 61
28393072 2017
28
The different functions and clinical significances of caveolin-1 in human adenocarcinoma and squamous cell carcinoma. 61
28243118 2017
29
[The molecular genetic alterations in mucosa of intestines as markers of oncologic progression and estimate of effectiveness of anti-reflux operations in patients with Barrett's esophagus]. 61
30615323 2016
30
Detection of human papillomavirus DNA in gastric carcinoma specimens in a high-risk region of Iran. 61
27588180 2016
31
Trajectory of body shape across the lifespan and cancer risk. 61
26704725 2016
32
Four Synchronous Primary Malignancies of the Breast, Lung, Colon and Esophagus. 61
26504043 2015
33
Simultaneous Esophageal Squamous Cell Carcinoma and Adenocarcinoma: A Case Report. 61
26609356 2015
34
Predictive Value of the Neutrophil/Lymphocyte Ratio in Peritoneal and/or Metastatic Disease at Staging Laparoscopy for Gastric and Esophageal Adenocarcinoma. 61
25952408 2015
35
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. 61
25947566 2015
36
Analysis of AC3-33 gene expression in multiple organ cancer and adjacent normal tissue by RNA in situ hybridization. 61
26137149 2015
37
In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma. 61
24708360 2015
38
Four cases of adenocarcinoma of esophagus with co-existing hydatid cyst of liver which caused delayed management of carcinoma esophagus. 61
24869991 2015
39
Prolonged Impacted Denture in the Esophagus: A Case Report and Review of the Literature. 61
27162898 2015
40
Unusual metastasis of esophageal cancer. 61
25518280 2014
41
Esophagus adenocarcinoma in a young patient with celiac disease; Is celiac disease a predisposing factor for esophagus adenocarcinoma as well as squamous cell carcinoma? 61
26185881 2014
42
Research on the typical miRNA and target genes in squamous cell carcinoma and adenocarcinoma of esophagus cancer with DNA microarray. 61
24519530 2014
43
OCT3 and SOX2 promote the transformation of Barrett's esophagus to adenocarcinoma by regulating the formation of tumor stem cells. 61
24481676 2014
44
Radiotherapy in the multimodality management of esophageal cancer. 61
25799618 2014
45
Esophagogastric metaplasia relates to nodal metastases in adenocarcinoma of esophagus and cardia. 61
23434259 2013
46
MUTYH association with esophageal adenocarcinoma in a Han Chinese population. 61
24377542 2013
47
Increase of epidermal growth factor receptor expression in progression of GERD, Barrett, and adenocarcinoma of esophagus. 61
22875307 2013
48
Aberrant expression of Wnt and Notch signal pathways in Barrett's esophagus. 61
22889748 2012
49
Association of methylenetetrahydrofolate reductase C677T-A1298C polymorphisms with risk for esophageal adenocarcinoma, Barrett's esophagus, and reflux esophagitis. 61
21951971 2012
50
Comparative evaluation of serum C-reactive protein (CRP) levels in the different histological subtypes of esophageal cancer (squamous cell carcinoma and adenocarcinoma of esophagus). 61
22467322 2012

Variations for Esophagus Adenocarcinoma

Expression for Esophagus Adenocarcinoma

Search GEO for disease gene expression data for Esophagus Adenocarcinoma.

Pathways for Esophagus Adenocarcinoma

Pathways related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.77 TP53 PTGS2 MIR330 MIR215 MIR21 MIR199A1
2 10.98 TP53 FGFR2 ERBB2
3 10.27 MIR199A1 MIR145

GO Terms for Esophagus Adenocarcinoma

Biological processes related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 PTGS2 MIR21 FGFR2 ERBB2 CDX2
2 sodium ion export across plasma membrane GO:0036376 9.54 ATP4A ATP12A
3 cellular potassium ion homeostasis GO:0030007 9.52 ATP4A ATP12A
4 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.5 MIR21 MIR199A1 MIR145
5 mesodermal cell differentiation GO:0048333 9.49 MIR145 FGFR2
6 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.48 ATP4A ATP12A
7 angiotensin-activated signaling pathway GO:0038166 9.46 MIR145 MIR143
8 aorta smooth muscle tissue morphogenesis GO:0060414 9.43 MIR145 MIR143
9 regulation of ERK1 and ERK2 cascade GO:0070372 9.43 MIR145 FGFR2 ERBB2
10 negative regulation of interleukin-21 production GO:0032705 9.4 MIR215 MIR21
11 regulation of phenotypic switching GO:1900239 9.37 MIR145 MIR143
12 positive regulation of protein kinase B signaling GO:0051897 9.35 MIR21 MIR199A1 MIR143 FGFR2 ERBB2
13 gene silencing by miRNA GO:0035195 9.23 MIR362 MIR330 MIR215 MIR21 MIR199A1 MIR196A1
14 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.16 MIR145 MIR143

Molecular functions related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.46 TP53 MIR21 MIR145 MIR143
2 oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen GO:0016702 9.37 PTGS2 CDO1
3 sodium:potassium-exchanging ATPase activity GO:0005391 9.32 ATP4A ATP12A
4 potassium-transporting ATPase activity GO:0008556 9.26 ATP4A ATP12A
5 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR362 MIR330 MIR215 MIR21 MIR199A1 MIR196A1
6 potassium:proton exchanging ATPase activity GO:0008900 8.96 ATP4A ATP12A

Sources for Esophagus Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....